Loading stock data…
Cryoport (CYRX)
$16.28+0.28 (+1.75%)
After Hours$16.28+0.00 (+0.00%)· Last close Jun 29
Cryoport, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cryoport, Inc. in the Industrials sector is trading at $16.28 with a market capitalization of $741M. Wall Street consensus targets $15.61 (9 analysts), implying a -4.1% move over the next 12 months. The stock is currently near its 52-week high of $16.73, remaining 57.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $47.80M↑ | $45.45M↑ | $44.23M↓ | $45.45M↑ | $41.04M |
| Gross Profit | $21.91M↑ | $21.71M↑ | $21.32M↓ | $21.38M↑ | $18.64M |
| Operating Income | -$9.61M↑ | -$10.03M↓ | -$9.93M↓ | -$9.65M↓ | -$7.19M |
| Net Income | -$10.54M↑ | -$11.64M↓ | -$6.94M↓ | $105.18M↑ | -$11.98M |
Peer Comparison
Fundamentals
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostora...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$741.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.36%
Volume
Today's trading volume
947,423
Recent News
Cryoport (CYRX) Stock Fair Value Rises After Analysts Revisit Bioservices Outlook
Cryoport’s analyst assessed fair value per share has been updated to US$15.61 from US$13.61, signaling a shift in how research teams are framing the stock’s intrinsic worth. Behind this change, recent reports highlight on the ground work around bioservices operations, with analysts debating how differentiated offerings, demand patterns and cost structure might influence execution and risk around current targets. Read on to see what is driving this evolving narrative and how you can track it...
Cryoport, Inc. Q1 2026 Earnings Call Summary
Moby summary of Cryoport, Inc.'s Q1 2026 earnings call
Cryoport (CYRX) Q1 2026 Earnings Transcript
As a reminder, Cryoport, Inc. has uploaded their first quarter 2026 in review document to the main page of the Cryoport, Inc. website. This document provides a review of Cryoport, Inc.'s financial and operational performance and the general business outlook. Before I turn the call over to Jerry, please note that because of the strategic partnership that has been established with DHL Group, and the related sale of Cryo PDP to DHL in June 2025, Cryo PDP's financials, which were previously a part of Cryoport, Inc.'s Life Sciences Services reportable segment, are now presented as discontinued operations.
CryoPort Q1 Earnings Call Highlights
CryoPort (NASDAQ:CYRX) reported first-quarter fiscal 2026 results that management said reflected continued momentum across its integrated services and products platform, highlighted by double-digit revenue growth in both reporting segments and improved profitability metrics. On the call, CEO Jerrel
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CryoPort (CYRX) delivered earnings and revenue surprises of -15.00% and +6.41%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?